FGFR4 c.1162G > A (p.Gly388Arg) Polymorphism Analysis in Turkish Patients with Retinoblastoma
Table 2
Association of FGFR4 p.Gly388Arg variant with clinicopathologic variants.
Clinicopathologic features
Wild-type GG no. (%)
Heterozygous GA no. (%)
Homozygous AA no. (%)
Total no. (%)
Significance, P value
Age (months), mean 21 ± 4, range (1–216)
<24 months
15 (68.2%)
11 (50%)
5 (100%)
31 (63.3%)
0.04
≥24 months
7 (31.8%)
11 (50%)
0 (0%)
18 (36.7%)
Total
22
22
5
49
Sex
Female
15 (68.2%)
12 (54.5%)
1 (20%)
28 (57.1%)
0.137
Male
7 (31.8%)
10 (45.5%)
4 (80%)
21 (42.9%)
Total
22
22
5
49
Diagnosis
Unilateral
18 (81.8%)
20 (90.9%)
5 (100%)
43 (87.8%)
0.444
Bilateral
4 (18.2%)
2 (9.1%)
0 (0%)
6 (12.2%)
Total
22
22
5
49
Leukocoria
Yes
17 (77.3%)
16 (72.7%)
4 (80%)
37 (75.5%)
0.912
No
5 (22.7%)
6 (27.3%)
1 (20%)
12 (24.5%)
Total
22
22
5
49
Strabismus
Esodeviation
10 (45.5%)
7 (31.8%)
2 (40%)
19 (38.8%)
0.929
Exodeviation
4 (18.1%)
5 (22.7%)
1 (20%)
10 (20.4%)
No
8 (36.4%)
10 (45.5%)
2 (40%)
20 (40.8%)
Total
22
22
5
49
Glaucoma
Yes
5 (22.7%)
2 (9.1%)
0 (0%)
7 (14.3%)
0.201
No
17 (77.3%)
20 (90.9%)
5 (100%)
42 (85.7%)
Total
22
22
5
49
Stage
Early stage
8 (36.4%)
3 (13.6%)
0 (0%)
11 (22.4%)
0.031
Late stage
14 (63.6%)
19 (86.4%)
5 (100%)
38 (77.6%)
Total
22
22
5
49
Treatment
IAC
Yes
10 (45.5%)
12 (54.5%)
4 (80%)
26 (53.1%)
0.370
No
12 (54.5%)
10 (45.5%)
1 (20%)
23 (46.9%)
Total
22
22
5
49
CT
Yes
10 (45.5%)
8 (36.4%)
1 (20%)
19 (38.8%)
0.546
No
12 (54.5%)
14 (63.6%)
4 (80%)
30 (61.2%)
Total
22
22
5
49
RT
Yes
2 (9.1%)
0 (0%)
0 (0%)
2 (4.1%)
0.278
No
20 (90.9%)
22 (100%)
5 (100%)
47 (95.9%)
Total
22
22
5
49
Surgery (enucleation)
Yes
11 (50%)
9 (40.9%)
0 (0%)
20 (40.8%)
0.05
No
11 (50%)
13 (59.1%)
5 (100%)
29 (59.2%)
Total
22
22
5
49
LOT
Yes
3 (13.6%)
4 (18.2%)
0 (0%)
7 (14.3%)
0.573
No
19 (86.4%)
18 (81.8%)
5 (100%)
42 (85.7%)
Total
22
22
5
49
Wild-type GG allele; c. [1162G > G]; [1162G > G], heterozygous GA allele; c. [1162G > G]; [1162G > A], homozygous AA; c. [1162G > G]; [1162A > A]. Early stage, group A, group B, and group C; late stage, group D or group E; IAC, intra-arterial chemotherapy; CT, chemotherapy; RT, radiotherapy; surgery, enucleation of eye; LOT, local ophthalmic treatment (cryotherapy, thermotherapy, and laser therapy); is significant.
